Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;31(6):895-905.
doi: 10.5603/cj.99752. Epub 2024 Nov 21.

Transcatheter mitral valve replacement - a new option for a selected group of patients?

Mariusz Kuśmierczyk  1 , Adam Witkowski  2 , Michał Zembala  3   4 , Bogusław Kapelak  5 , Marcin Gruchała  6 , Andrzej Gackowski  7   8 , Marek Deja  9 , Wojciech Wojakowski  10 , Marek Grygier  11 , Marcin Grabowski  12 , Ewa Kowalik  13 , Piotr Przygodzki  14 , Maciej Niewada  15   16 , Michał Jakubczyk  17   18
Affiliations
Review

Transcatheter mitral valve replacement - a new option for a selected group of patients?

Mariusz Kuśmierczyk et al. Cardiol J. 2024.

Abstract

Mitral regurgitation (MR) is the second most common valvular disease. Symptomatic MR is associated with a poor prognosis. Cardiac surgery is recommended in the severe form of the disease. If the surgical risk is high or functional mitral regurgitation repair/replacement cannot be combined with aorto-coronary bypass graft surgery, a transcatheter edge-to-edge valve repair should be considered. Currently, there is no recommended procedure in patients with severe symptomatic MR, high cardiac surgical risk, and low probability of success or contraindications to the percutaneous edge-to-edge treatment. A recent alternative is the mitral valve implantation using a transapical approach or through the interatrial septum. Currently, the only CE-marked transcatheter bioprothesis valve using transapical approach and implanted without extracorporeal circulation support is the Tendyne valve. This paper discusses the safety, clinical efficacy and cost effectiveness of this valve and the size of the target population in Poland. The clinical efficacy was evaluated in a study of 100 patients with severe symptomatic MR. The total 2-year mortality was 39%. The hospitalisation rate due to heart failure decreased from 1.3 events/year prior to the surgery to 0.51. MR was not recorded in 93.2% of the survivors. An economic analysis accounting for the survival, health-related quality of life, and the risk of hospitalisation due to heart failure showed that the Tendyne system is cost-effective compared to pharmacological treatment: the incremental cost-utility ratio equalled 93,324-110,696 PLN, depending on the approach, clearly below the official threshold in Poland. The annual number of eligible patients was estimated at 60.

Keywords: Tendyne; cost-effectiveness; mitral regurgitation; mitral valve implantation.

PubMed Disclaimer

Conflict of interest statement

Conflict of interests: A. Gackowski declares proctoring and lecture honoraria from Abbott and from Edwards Lifesciences. M. Grygier is a proctor for Abbott and reports speaker’s or consulting honoraria from Abbott, Medtronic, Edwards Lifesciences, and 4cMedical. M. Grabowski declares speaker honoraria from Abbott Medical. M. Jakubczyk and M. Niewada are co-owners of HealthQuest, a consultancy receiving payments from Abbott.

Figures

Central illustration
Central illustration
The Tendyne system
Figure 1
Figure 1
Overall survival — original data from the Muller (2021) study and extrapolation (after 24 months)
See this image and copyright information in PMC

References

    1. Iung B, Delgado V, Rosenhek R, et al. Contemporary presentation and management of valvular heart disease: the eurobservational research programme valvular heart disease II survey. Circulation. 2019;140(14):1156–1169. doi: 10.1161/CIRCULATIONAHA.119.041080. - DOI - PubMed
    1. Cahill TJ, Prothero A, Wilson Jo, et al. Community prevalence, mechanisms and outcome of mitral or tricuspid regurgitation. Heart. 2021;107(12):1003–1009. doi: 10.1136/heartjnl-2020-318482. - DOI - PubMed
    1. McCarthy KP, Ring L, Rana BS. Anatomy of the mitral valve: understanding the mitral valve complex in mitral regurgitation. Eur J Echocardiogr. 2010;11(10):i3–i9. doi: 10.1093/ejechocard/jeq153. - DOI - PubMed
    1. Nogara A, Minacapelli A, Zambelli G, et al. Functional anatomy and echocardiographic assessment in secondary mitral regurgitation. J Card Surg. 2022;37(12):4103–4111. doi: 10.1111/jocs.16863. - DOI - PubMed
    1. Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28(11):1358–1365. doi: 10.1093/eurheartj/ehm001. - DOI - PubMed

MeSH terms

LinkOut - more resources